Biotron's BIT225 Shows Strong Hep C Antiviral Activity
Biotron study of lead Hepatitis C drug shows virus undetectable in patients after three months
Wednesday, December 07, 2011 by Angela Kean
Biotron (ASX: BIT) has revealed positive results from a phase 2a trial of its lead Hepatitis C drug candidate, BIT225, that show 87% of patients receiving the drug had an undetectable virus after three months of treatment.
BIT225 targets the viral protein p7, which plays a crucial role in virus replication and reproduction. It is a new target, and BIT225 is a first-in-class direct acting antiviral.
The 28 day study treated patients with a combination of BIT225 and current approved standard of care therapies interferon alfa-2b plus ribavirin.
Continue reading this entire article:
Initial Hep C Data on ACH-2928 Is Encouraging
Green Tea and Hepatitis C Post Liver Transplant